Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseasePenile CarcinomaSubgroupICD10C60.-MeSHPenile NeoplasmsUrethral NeoplasmsSequenceChemotherapyChemo-substanceCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelVinfluninChemo-substanceCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelVinfluninChemo-substanceCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelVinfluninChemo-substanceCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelVinfluninNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideNo. Substances3578910Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseneoadjuvantneoadjuvant / adjuvantTherapy intentioncurativepalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperglycemiaInfectionsMucositisNeuropathyNeutropeniaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDi Lorenzo GHussein ANecchi ANicholson SPagliaro LPizzocarro GDiseasePatienten mit primär nicht resektablen Lymphnotenmetastasen oder Rezidiv der LymphknotenmetastasenPenis-Ca, vortherapiert mit CisplatinPeniskarzinom, metastasiert oder lokal fortgeschritten, ECOG 0-1Peniskarzinom, metastasiert oder lokal fortgeschritten, ECOG 0-2Peniskarzinom im Stadium cTx, cN2/N3, cM0, ECOG 0-2, neoadjuvante TherapieRezidiviertes oder nicht-resezierbares Penis-/UrethrakarzinomOriginDepartment of Genitourinary Medical Oncology, The University of Texas, Houston, TexasDepartment of Medical Oncology, Charing Cross Hospital, London, UKDepartment of Medical Oncology, Charing Cross Hospital, London, UK, CRUK/09/001 trialFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Her-Uro-01 trialGenitourinary Oncology and Rare Cancer Center, Federico II University, Naples, ItalySylvester Comprehensive Cancer Center, University of Miami School of Medicine, FloridaUrologic Clinic 2nd, S. Giuseppe Hospital, Milan University, Milan, ItalyProtocols in Revision 7 protocols foundProtocols under revision.Cisplatin 100 / Fluorouracil 960, Penile Carcinoma (PID1443 V1.2)Dacomitinib 45, Penile Carcinoma (PID2742 V1.0)Docetaxel 75 / Cisplatin 60 / Fluorouracil 750, Penile Carcinoma (PID2740 V1.0)Paclitaxel 120 / Cisplatin 50 / Fluorouracil 1000, Penile Carcinoma (PID1442 V1.2)Paclitaxel 175, Penile Carcinoma (PID1648 V1.0)TIP (Paclitaxel 175 / Ifosfamide 1.2 / Cisplatin 25), Penile Carcinoma, neoadjuvant / adjuvant. (PID1444 V1.1)Vinflunin 320, Penile Carcinoma (PID2741 V1.0)
